The stock's fall snapped a three-day winning streak.

Vertex Pharmaceuticals Inc. closed 10.29% short of its 52-week high of $519.88, which the company achieved on November 8th.

Investing at least part of the initial $1,000 in an artificial intelligence (AI) stock is a smart move. Despite impressive ...

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

Now, it’s worth noting Stock Advisor’s total average return is 1,049% — a market-crushing outperformance compared to 180% for ...

See the latest Vertex Pharmaceuticals Inc stock price (VRTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Read about Vertex Pharmaceuticals Inc (VRTX:XNAS) stock and today's latest news and financial updates.

Calidi Biotherapeutics Inc. has spent over 10 years developing a groundbreaking platform for the systemic delivery of genetic medicines that can precisely target tumors. One of the company's core ...

Vertex Pharmaceuticals secured European approval for Alyftrek, reinforcing its dominance in cystic fibrosis treatment as ...